![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1314532 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC35G2 mRNA | CTD | PMID:26238291 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1306109 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC35G2 mRNA | CTD | PMID:32109520 | 2-methylcholine | affects expression | ISO | RGD:1314532 | 6480464 | beta-methylcholine affects the expression of SLC35G2 mRNA | CTD | PMID:21179406 | aflatoxin B1 | increases expression | ISO | RGD:1314532 | 6480464 | Aflatoxin B1 results in increased expression of SLC35G2 mRNA | CTD | PMID:21641981, PMID:27153756 | amphetamine | increases expression | ISO | RGD:1306109 | 6480464 | Amphetamine results in increased expression of SLC35G2 mRNA | CTD | PMID:30779732 | benzo[a]pyrene | increases expression | ISO | RGD:1314532 | 6480464 | Benzoapyrene results in increased expression of SLC35G2 mRNA | CTD | PMID:20064835 more ... | benzo[a]pyrene | affects methylation | ISO | RGD:1314532 | 6480464 | Benzoapyrene affects the methylation of SLC35G2 promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases methylation | ISO | RGD:1314532 | 6480464 | Benzoapyrene results in decreased methylation of SLC35G2 5' UTR | CTD | PMID:27901495 | benzo[a]pyrene | multiple interactions | EXP | | 6480464 | [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of SLC35G2 mRNA | CTD | PMID:27858113 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:1314532 | 6480464 | 7 more ... | CTD | PMID:19150397 | benzo[b]fluoranthene | multiple interactions | EXP | | 6480464 | [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of SLC35G2 mRNA | CTD | PMID:27858113 | bisphenol A | decreases expression | ISO | RGD:1306109 | 6480464 | bisphenol A results in decreased expression of SLC35G2 mRNA | CTD | PMID:25181051 | carbamazepine | affects expression | ISO | RGD:1314532 | 6480464 | Carbamazepine affects the expression of SLC35G2 mRNA | CTD | PMID:25979313 | chrysene | multiple interactions | EXP | | 6480464 | [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of SLC35G2 mRNA | CTD | PMID:27858113 | copper atom | multiple interactions | ISO | RGD:1314532 | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of SLC35G2 mRNA | CTD | PMID:20971185 | copper(0) | multiple interactions | ISO | RGD:1314532 | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of SLC35G2 mRNA | CTD | PMID:20971185 | copper(II) sulfate | increases expression | ISO | RGD:1314532 | 6480464 | Copper Sulfate results in increased expression of SLC35G2 mRNA | CTD | PMID:19549813 | cyclosporin A | increases expression | ISO | RGD:1314532 | 6480464 | Cyclosporine results in increased expression of SLC35G2 mRNA | CTD | PMID:20106945, PMID:25562108 | cylindrospermopsin | increases expression | ISO | RGD:1314532 | 6480464 | cylindrospermopsin results in increased expression of SLC35G2 mRNA | CTD | PMID:24921660 | diuron | decreases expression | ISO | RGD:1306109 | 6480464 | Diuron results in decreased expression of SLC35G2 mRNA | CTD | PMID:21551480 | dorsomorphin | multiple interactions | ISO | RGD:1314532 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... | CTD | PMID:27188386 | entinostat | increases expression | ISO | RGD:1314532 | 6480464 | entinostat results in increased expression of SLC35G2 mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | RGD:1314532 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SLC35G2 mRNA | CTD | PMID:27188386 | hydrogen peroxide | affects expression | ISO | RGD:1314532 | 6480464 | Hydrogen Peroxide affects the expression of SLC35G2 mRNA | CTD | PMID:20044591 | lead(0) | affects expression | ISO | RGD:1314532 | 6480464 | Lead affects the expression of SLC35G2 mRNA | CTD | PMID:28903495 | lead(2+) | affects expression | ISO | RGD:1314532 | 6480464 | Lead affects the expression of SLC35G2 mRNA | CTD | PMID:28903495 | leflunomide | increases expression | ISO | RGD:1314532 | 6480464 | leflunomide results in increased expression of SLC35G2 mRNA | CTD | PMID:28988120 | mercury dibromide | increases expression | ISO | RGD:1314532 | 6480464 | mercuric bromide results in increased expression of SLC35G2 mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | RGD:1314532 | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SLC35G2 mRNA | CTD | PMID:27188386 | methylmercury chloride | increases expression | ISO | RGD:1314532 | 6480464 | methylmercuric chloride results in increased expression of SLC35G2 mRNA | CTD | PMID:28001369 | p-chloromercuribenzoic acid | increases expression | ISO | RGD:1314532 | 6480464 | p-Chloromercuribenzoic Acid results in increased expression of SLC35G2 mRNA | CTD | PMID:26272509 | p-chloromercuribenzoic acid | multiple interactions | ISO | RGD:1314532 | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SLC35G2 mRNA | CTD | PMID:27188386 | panobinostat | multiple interactions | ISO | RGD:1314532 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SLC35G2 mRNA | CTD | PMID:27188386 | phenylmercury acetate | increases expression | ISO | RGD:1314532 | 6480464 | Phenylmercuric Acetate results in increased expression of SLC35G2 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1314532 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SLC35G2 mRNA | CTD | PMID:27188386 | quercetin | increases expression | ISO | RGD:1314532 | 6480464 | Quercetin results in increased expression of SLC35G2 mRNA | CTD | PMID:21632981 | SB 431542 | multiple interactions | ISO | RGD:1314532 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | RGD:1314532 | 6480464 | Silicon Dioxide analog results in increased expression of SLC35G2 mRNA | CTD | PMID:25895662 | sodium arsenite | increases expression | ISO | RGD:1314532 | 6480464 | sodium arsenite results in increased expression of SLC35G2 mRNA | CTD | PMID:21281968 | Soman | decreases expression | ISO | RGD:1306109 | 6480464 | Soman results in decreased expression of SLC35G2 mRNA | CTD | PMID:19281266 | sulforaphane | increases expression | ISO | RGD:1314532 | 6480464 | sulforafan results in increased expression of SLC35G2 mRNA | CTD | PMID:31838189 | tert-butyl hydroperoxide | increases expression | ISO | RGD:1314532 | 6480464 | tert-Butylhydroperoxide results in increased expression of SLC35G2 mRNA | CTD | PMID:15336504 | tetraphene | multiple interactions | EXP | | 6480464 | [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of SLC35G2 mRNA | CTD | PMID:27858113 | thapsigargin | increases expression | ISO | RGD:1314532 | 6480464 | Thapsigargin results in increased expression of SLC35G2 mRNA | CTD | PMID:29453283 | topotecan | affects response to substance | ISO | RGD:1314532 | 6480464 | SLC35G2 protein affects the susceptibility to Topotecan | CTD | PMID:16217747 | trichostatin A | increases expression | ISO | RGD:1314532 | 6480464 | trichostatin A results in increased expression of SLC35G2 mRNA | CTD | PMID:24935251 | valproic acid | affects expression | ISO | RGD:1314532 | 6480464 | Valproic Acid affects the expression of SLC35G2 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | RGD:1314532 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SLC35G2 mRNA | CTD | PMID:27188386 | valproic acid | increases expression | ISO | RGD:1314532 | 6480464 | Valproic Acid results in increased expression of SLC35G2 mRNA | CTD | PMID:23179753 more ... | zalcitabine | multiple interactions | ISO | RGD:1306109 | 6480464 | [gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of SLC35G2 mRNA | CTD | PMID:18606552 | |